Outcome Measures for Use in Treatment Trials of Individuals with Intellectual and Developmental Disabilities (R01 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

This funding opportunity announcement (FOA) encourages applications from institutions/organizations that propose to develop informative outcome measures for use in clinical trials for individuals with intellectual and developmental disabilities (IDD). This FOA will address a significant need in the field, one that is especially apparent in efforts to develop pharmacological treatments for these populations. This FOA will focus ongoing clinical and translational research on a neglected area essential for therapy and pharmacological treatment development.

Potential applicants may also be interested in the FOA “Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities (R01).”


  • Letter of Intent Due Date(s): 30 days before application due date
  • R01 Deadlines: Feb. 5, Jun. 5, Oct. 5.
  • AIDS Deadlines: Jan. 7, May 7, Sep. 7

PAR-18-039 Expiration Date May 8, 2019

Agency Website

Eligibility Requirements

Multidisciplinary teams that consist of an appropriate combination of: 1) researchers experienced in the conduct of behavioral, social emotional, educational and cognitive studies of children with IDD; 2) scientists with knowledge of neurological and/or physiological basis of the disorder; 3) researchers experienced in conducting clinical trials; 4) researchers experienced in the design of psychometric and/or medical assessments, and; 5) clinicians who treat individuals with IDD(s) are encouraged to apply. 



Amount Description

Budgets for direct costs of up to $499,999 per year may be requested for a maximum of $2,499,996 direct costs over a five-year project period.

The total project may not exceed 5 years 

    Funding Type





    Medical - Clinical Science
    Medical - Translational

    External Deadline

    February 5, 2019